

C-3169/1/US

99/451,641

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gao, D. et al.

Filing Date

November 30, 1999

Group No.

1615

U.S. PATENT DOCUMENTS

| Examiner Initial* | Patent Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
|-------------------|---------------|------------|--------------|----------------|----------|----------------------------|
| 3 | AC | 5,869,096 | Feb 9, 1999 | Barclay et al. | 424 468 | Dec 9, 1994 |
| | AD | 5,756,529 | May 26, 1998 | Isakson et al. | 514 406 | |
| | AE | 5,633,272 | May 27, 1997 | Talley et al. | 514 378 | |
| | AF | 5,474,784 | Dec 12, 1995 | Stevens et al. | 424 456 | |
| | AG | 5,342,624 | Aug 30, 1994 | McNeill et al. | 424 451 | |
| | AH | 4,866,848 | Sep 12, 1989 | Conte et al. | 424 466 | |
| 2 | AI | 4,681,755 | Jul 21, 1987 | Colombo et al. | 424 486 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial* | Document Number | Date | Country | Class | Subclass | Translation | |
|-------------------|-----------------|-------------|--------------|-------|-------------|-------------|----|
| | | | | | | Yes | No |
| 2 | BC | WO 97/44028 | Nov 27, 1997 | WIPO | A61K 31/365 | | X |
| 2 | BD | WO 99/09988 | Mar 4, 1999 | WIPO | A61K 31/54 | | X |

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

| | | |
|---|----|--|
| 2 | CD | Abdou (1989). Dissolution, Bioavailability and Bioequivalence, pp. 58-66, 457-458. Mack Publishing Co. |
| 4 | CE | American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5, 9-11, 26-33, 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129, 134-135, 138-140, 153-162, 166-169, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300, 304-308. |
| | CF | Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. |
| | CG | Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish; believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. |
| | CH | Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutical Dosage Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. |
| | CI | Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industrial Pharmacy, pp. 293-373. Lea & Febiger. |
| | CJ | DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutical Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. |
| | CK | Geçgil (1991). Farmasötik Teknolojiye Başlangıç (in Turkish; believed to translate as "Introduction to Pharmaceutical Technology"), pp. 346-348. No English translation available. |
| | CL | Güven (1979). İlaç Endüstrisi Teknolojisi (in Turkish; believed to translate as "Drug Industry Technology"), pp. 67-81. No English translation available. |
| | CM | Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American College of Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998. |
| | CN | Igzü (date unknown). Genel ve Endüstriyel Farmasötik Teknoloji (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology"), Vol. 1, pp. 367-382. No English translation available. |
| 3 | CO | Igzü (1983). Genel -- Endüstriyel Farmasötik Teknoloji -- II (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology -- II"), pp. 211-241. No English translation available. |


Examiner

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Applicant

Gao, D. *et al.*

Filing Date

November 30, 1999

Group No.

1615

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

- CP Karim *et al.* (1997). SC-58635 (celecoxib): a highly selective inhibitor of cyclooxygenase-2. Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation. *Pharmaceutical Research* 14, p. S-617, Abstr. 3469.
- CQ Kayaalp (date unknown). *Tibbi Farmakoloji* (In Turkish; believed to translate as "Medicinal Pharmacology"). Vol. 1, pp. 27-28 and Vol. 2, p. 1050. No English translation available.
- CR Lane (1997). Pain management in osteoarthritis: the role of COX-2 inhibitors. *Journal of Rheumatology* 24 (Supp. 49), 20-24.
- CS Parnham (1996). Inflammation: mechanisms and therapeutics. *Drug News & Perspectives* 9, 631-639.
- CT Peck *et al.* (1989). Tablet formulation and design. In Lieberman *et al.* (ed.) *Pharmaceutical Dosage Forms: Tablets*, 2nd ed., Vol. 1, pp. 75-130. Marcel Dekker.
- CU Proudfoot (1990). Factors influencing bioavailability: factors influencing drug absorption from the gastrointestinal tract. In Aulton (ed.) *Pharmaceutics, The Science of Dosage Form Design*, p. 156.
- CV Rubinstein (1990). Tablets. In Aulton (ed.) *Pharmaceutics, The Science of Dosage Form Design*, pp. 304-321.
- CW Shangraw (1989). Compressed tablets by direct compression. In Lieberman *et al.* (ed.) *Pharmaceutical Dosage Forms: Tablets*, 2nd ed., Vol. 1, pp. 195-246. Marcel Dekker.
- CX Wadke *et al.* (1989). Preformulation testing. In Lieberman *et al.* (ed.) *Pharmaceutical Dosage Forms: Tablets*, 2nd ed., Vol. 1, pp. 1-73. Marcel Dekker. See pp. 5, 47-48.
- CY Welling *et al.* (1991). *Pharmaceutical Bioequivalence*, pp. 413-414. Marcel Dekker.

Examiner

Date Considered

6/1/00

* Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAY 11 2002
TECH CENTER 1600/2900

C-3169/1/US

09/451,641

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gao, D. et al.

Filing Date

November 30, 1999

Group No.

1615

U.S. PATENT DOCUMENTS

| Examiner Initial* | | Patent Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
|-------------------|----|---------------|--------------|----------------------|-------|----------|----------------------------|
| | AJ | 6,040,850 | Apr 11, 2000 | Young et al. | 514 | 183 | Jul 7, 1995 |
| | AK | 5,932,576 | Aug 3, 1999 | Anantanarayan et al. | 514 | 235.5 | May 22, 1998 |
| | AL | 5,739,166 | Apr 14, 1998 | Reitz et al. | 514 | 602 | |
| | AM | 5,643,933 | Jul 1, 1997 | Talley et al. | 514 | 372 | |
| | AN | 5,540,669 | Jul 30, 1996 | Sage et al. | 604 | 290 | |
| | AO | 5,474,995 | Dec 12, 1995 | Ducharme et al. | 514 | 241 | |
| | AP | 4,865,849 | Sep 12, 1989 | Conte et al. | 424 | 466 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial* | | Document Number | Date | Country | Class | Subclass | Translation | |
|-------------------|----|-----------------|--------------|---------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| | BE | WO 95/00501 | Jan 5, 1995 | WIPO | C07D | 277/02 | | X |
| | BF | WO 95/15316 | Jun 08, 1995 | WIPO | C07D | 231/12 | | X |
| | BG | WO 95/18799 | Jul 13, 1995 | WIPO | C07D | 307/58 | | X |

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

| | | | | | | | |
|--|----|---|--|--|--|--|--|
| | CZ | Barkin (1997). Cancer pain treatment insights. Pharmacotherapy 17(2), pp. 397-398. | | | | | |
| | DA | Burger & Wachter (1998). Hunnius - Pharmazeutisches Wörterbuch (in German; believed to translate as "Pharmaceutical Dictionary"), 8th Edition. Walter de Gruyter. Berlin, New York, pp. 278, 854, 954, 1109. English translation provided. | | | | | |
| | DB | Lipsky (1999). COX-2 specific inhibitors: basic science and clinical implications. Amer. J. Med. 106(5B), pp. 1S-2S. | | | | | |
| | DC | Raskin (1999). Gastrointestinal effects of nonsteroidal anti-inflammatory activity. Amer. J. Med. 106(5B), pp. 3S-12S. | | | | | |
| | DD | Radebaugh & Ravin (1995). Preformulation. In Remington's Pharmacy, 19th edition, Vol. II, Chap. 83. Mack Publishing Group, p. 1449. | | | | | |
| | DE | Serafin (1996). Drugs used in the treatment of asthma. In Goodman & Gilman's Pharmacological Basis of Therapeutics, 9th edition, Chap. 28. McGraw-Hill, p. 665. | | | | | |
| | DF | Voigt (1993). Pharmazeutische Technologie für Studium und Beruf (in German; believed to translate as "Pharmaceutical Technology for the Classroom and Professional Applications"), 7th edition. Ulstein Mosby GmbH & Co. KG Berlin, pp. 40-43, 119, 210-212, 231-238. English translation provided. | | | | | |
| | DG | Whelton (1999). Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Amer. J. Med. 106(5B), pp. 13S-24S. | | | | | |

Examiner

Date Considered

* Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

C-3169/1/US

09/451,641

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gao, D. et al.

Filing Date

November 30, 1999

Group No.

1615

U.S. PATENT DOCUMENTS

| Examiner Initial* | | Patent Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
|-------------------|----|---------------|--------------|----------------|-------|----------|----------------------------|
| | AC | 5,869,096 | Feb 9, 1999 | Barclay et al. | 424 | 468 | Dec 9, 1994 |
| | AD | 5,756,529 | May 26, 1998 | Isakson et al. | 514 | 406 | |
| | AE | 5,633,272 | May 27, 1997 | Talley et al. | 514 | 378 | |
| | AF | 5,474,784 | Dec 12, 1995 | Stevens et al. | 424 | 456 | |
| | AG | 5,342,624 | Aug 30, 1994 | McNeill et al. | 424 | 451 | |
| | AH | 4,866,848 | Sep 12, 1989 | Conte et al. | 424 | 466 | |
| | AI | 4,681,755 | Jul 21, 1987 | Colombo et al. | 424 | 486 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial* | | Document Number | Date | Country | Class | Subclass | Translation | |
|-------------------|----|-----------------|--------------|---------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| | BC | WO 97/44028 | Nov 27, 1997 | WIPO | A61K | 31/365 | | X |
| | BD | WO 99/09988 | Mar 4, 1999 | WIPO | A61K | 31/54 | | X |

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

| | | |
|--|----|--|
| | CD | Abdou (1989). Dissolution, Bioavailability and Bioequivalence, pp. 58-66, 457-458. Mack Publishing Co. |
| | CE | American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5, 9-11, 26-33, 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129, 134-135, 138-140, 153-162, 166-169, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300, 304-308. |
| | CF | Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713. |
| | CG | Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish; believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available. |
| | CH | Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutical Dosage Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker. |
| | CI | Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industrial Pharmacy, pp. 293-373. Lea & Febiger. |
| | CJ | DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutical Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co. |
| | CK | Geçgil (1991). Farmasötik Teknolojiye Başlangıç (In Turkish; believed to translate as "Introduction to Pharmaceutical Technology"), pp. 346-348. No English translation available. |
| | CL | Güven (1979). İlaç Endüstrisi Teknolojisi (In Turkish; believed to translate as "Drug Industry Technology"), pp. 67-81. No English translation available. |
| | CM | Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American College of Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998. |
| | CN | Igzü (date unknown). Genel ve Endüstriyel Farmasötik Teknoloji (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology"), Vol. 1, pp. 367-382. No English translation available. |
| | CO | Igzü (1983). Genel - Endüstriyel Farmasötik Teknoloji - II (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology - II"), pp. 211-241. No English translation available. |

Examiner

Date Considered

11/24/00

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

C-3169/1/US

09/451,641

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gao, D. *et al.*

Filing Date

November 30, 1999

Group No.

1615

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

- | | |
|----|--|
| CP | Karim <i>et al.</i> (1997). SC-58635 (celecoxib): a highly selective inhibitor of cyclooxygenase-2. Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation. <i>Pharmaceutical Research</i> 14, p. S-617, Abstr. 3469. |
| CQ | Kayaalp (date unknown). <i>Tibbi Farmakoloji</i> (In Turkish; believed to translate as "Medicinal Pharmacology"), Vol. 1, pp. 27-28 and Vol. 2, p. 1050. No English translation available. |
| CR | Lane (1997). Pain management in osteoarthritis: the role of COX-2 inhibitors. <i>Journal of Rheumatology</i> 24 (Supp. 49), 20-24. |
| CS | Parnham (1996). Inflammation: mechanisms and therapeutics. <i>Drug News & Perspectives</i> 9, 631-639. |
| CT | Peck <i>et al.</i> (1989). Tablet formulation and design. In Lieberman <i>et al.</i> (ed.) <i>Pharmaceutical Dosage Forms: Tablets</i> , 2nd ed., Vol. 1, pp. 75-130. Marcel Dekker. |
| CU | Proudfoot (1990). Factors influencing bioavailability: factors influencing drug absorption from the gastrointestinal tract. In Aulton (ed.) <i>Pharmaceutics, The Science of Dosage Form Design</i> , p. 156. |
| CV | Rubinstein (1990). Tablets. In Aulton (ed.) <i>Pharmaceutics, The Science of Dosage Form Design</i> , pp. 304-321. |
| CW | Shangraw (1989). Compressed tablets by direct compression. In Lieberman <i>et al.</i> (ed.) <i>Pharmaceutical Dosage Forms: Tablets</i> , 2nd ed., Vol. 1, pp. 195-246. Marcel Dekker. |
| CX | Wadke <i>et al.</i> (1989). Preformulation testing. In Lieberman <i>et al.</i> (ed.) <i>Pharmaceutical Dosage Forms: Tablets</i> , 2nd ed., Vol. 1, pp. 1-73. Marcel Dekker. See pp. 5, 47-48. |
| CY | Welling <i>et al.</i> (1991). <i>Pharmaceutical Bioequivalence</i> , pp. 413-414. Marcel Dekker. |

Examiner

Date Considered

12/7/99

* Examiner Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant